npj Breast Cancer · 2023 · 25 citations · 13 references
MedicineCancer BiologyOncologyBreast OncologyEndocrine OncologyMolecular OncologyBreast Cancer OncologyCancer BiomarkersEndocrine Tumor PrognosisHer2-positive Breast CancerHormonal Cancer TherapyMetastatic Breast CancerBiomarker-based Prognostic ModelsBreast Cancer Molecular SubtypesHer2 AmplificationHer2 InhibitorsHer2-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionHuman Epidermal Growth Factor Receptor 2-Targeted TherapyPrognostic Biomarker Discovery
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
13
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 691 citations · Full text
Medicine, Cancer Biology, Oncology +10
Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations
Medicine, Cancer Biology, Oncology +16
Evolution of HER2-low expression from primary to recurrent breast cancer
Federica Miglietta, Gaia Griguolo, Michele Bottosso et al. · npj Breast Cancer · 2021 · 226 citations · Full text
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
Paolo Tarantino, Qingchun Jin, Nabihah Tayob et al. · JAMA Oncology · 2022 · 202 citations · Full text